Transatlantic Australasian Retroperitoneal Sarcoma Working Group

A collaborative group for Surgical Oncologists and Sarcoma Professionals

Open studies / projects

INTERNATIONAL MULTI-INSTITUTIONAL RESEARCH BY TARPSWG

Check out the Studies that have been done and are currently recruiting for Collaborative Research:

FOR MORE INFORMATION ON ANY OF THESE STUDIES PLEASE CONTACT: tarpswg@gmail.com

Studies open to accrual

TARPSWG RETROSPECTIVE STUDIES

No Open Studies Currently

RESAR PROSPECTIVE STUDIES

No Open Studies Currently

Closed studies – in progress

TARPSWG RETROSPECTIVE STUDIES

TARPSWG – 2101

Retroperitoneal Lipoma: How rare are they? By the TARPSWG group

  • PI: William Tseng MD (University of Southern California, Los Angeles, US); Alessandro Gronchi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy); Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US)
  • Co-I: Andre Oliveira, MD ; Judith Jebastin Thangaiah, MD (Mayo Clinic Rochester, US)
  • Status: Closed
  • Eligibility: Primary Retroperitoneal (RP) Lipomatous Tumors – including lipoma, WD liposarcoma, and angiomyolipoma. Our focus will ultimately be on RP lipomas. Minimum of 1 case required to enter the study

TARPSWG – 2102

The natural history of primary, extra-visceral, perivascular epitheloid cel tumours (PEComa) of the Retroperitoneum: The combined experience of the TARPSWG

  • PI: David Gyorki MD (Peter MacCallum Cancer Center, Melbourne, Australia)
  • Co-Is: Sameer Apte MD, Hayden Snow MD, Catherine Micthell MD (Peter MacCallum Cancer Center, Melbourne, Australia)
  • Status: Closed
  • Eligibility: Patients 18 years or older diagnosed with a primary, extra-visceral, retroperitoneal or abdominopelvic PEComa, or a tumour belonging to the family of PEComas over the past 10 years. Minimum of 1 case required to enter the study

TARPSWG – 2103

Evaluating international patterns of textbook outcomes in surgical resection of retroperitoneal sarcoma: A TARPSWG Study.

  • PI: Joal Beane MD (The Ohio State James Comprehensive Cancer Center)
  • Co-Is: Raphael Pollock MD, Valerie Grignol MD, Farhan Ilyas MD (The Ohio State James Comprehensive Cancer Center)
  • Status: Closed
  • Eligibility: All patients 18 years or older undergoing resection of retroperitoneal sarcoma from January 2010 to December 2020 with the intention of curative treatment. Minimum of 10 cases required to enter the study.

TARPSWG – 2002

Spermatic Cord Sarcomas – A Retrospective Analysis of Diagnosis, Clinical Features, Treatment Patterns and Outcomes (SARCORD) – A study by TARPSWG

  • PI: Sinziana Dumitra MD (McGill University, Montreal, Canada)
  • Co-I: Alessandro Gronchi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
  • Status: Closed
  • Eligibility: Any center can contribute to this study. All patients who have a primary soft tissue sarcoma originating from the spermatic cord between Jan 2005 and Dec 2018. Minimum of 1 case required to enter the study

TARPSWG-2009

The Natural History of Well-differentiated Liposarcoma in the Retroperitoneum: A TARPSWG Study

  • PIs: Mark Fairweather, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US); Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US)
  • Status: Closed, Currently Analyzing Data

TARPSWG-2001

The Evaluation and Outcome of Mesenteric and Intra-Abdominal Desmoids: A study by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)

  • PIs: Carolyn Nessim, MD, MSc (The Ottawa Hospital, Ottawa, Canada) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
  • Co-I: Kerianne Boulva, MD (The Ottawa Hospital, Ottawa, Canada)
  • Status: Closed, Data Clean Up

TARPSWG-2003

The Natural History of Ganglioneuroma: A Study by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)

  • PI: Jason Sicklick, MD (Moores Cancer Center, University of California San Diego Health System, San Diego, US)
  • Co-Is: Sangkyu Noh, MS (Moores Cancer Center, University of California San Diego Health System, San Diego, US) ; Carolyn Nessim, MD, MSc, (The Ottawa Hospital, Ottawa, Canada)
  • Status: Closed, Manuscript in Progress

TARPSWG-1803

Retroperitoneal Myxoid LPS: Always a Metastasis? A study by the Trans-Atlantic Australasian RPS Working Group (TARPSWG).

  • PIs: Carolyn Nessim, MD, MSc (The Ottawa Hospital, Ottawa, Canada) ; Chandrajit, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US)
  • Co-I: Bibianna Purgina, MD (The Ottawa Hospital, Ottawa, Canada)
  • Status: Closed, Awaiting Material for MDM2 testing

TARPSWG-1805

STREXIT – “off trial” management and outcomes of primary non-metastatic RPS at centres that participated in the STRASS trial

  • PIs: Carol Swallow, MD, PhD (Mount Sinai Hospital, Princess Margaret Hospital, University of Toronto, Toronto, Canada) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) ; Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US) ;Sylvie Bonvalot, MD (Institut Curie, PSL University, Paris, France)
  • Status: Closed, Manuscript in Progress

TARPSWG-1807

Pelvic Sarcomas – Retrospective Analysis of Clinical and Surgical Features and Outcomes (PELVISARC): A study by the Trans-Atlantic Australasian RPS Working Group (TARPSWG).

  • PIs: Marco Fiore, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) ; Sinziana Dumitra, MD (MgGill University Health Center, Montreal, Canada)
  • Co-I: Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
  • Status: Closed, Currently Analyzing Data

RESAR PROSPECTIVE STUDIES

TARPSWG – R1906

Benchmarks in RPS Surgery – A study by TARPSWG

  • PIs: Alessandro Gronchi MD, Marco Fiore MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy); Fabio Tirotta MD (University Hospital Birmingham NHS Foundation Trust, Birmingham, UK)
  • Status: Closed
  • Eligibility: Patients who underwent surgery for primary RPS at RESAR participating centers between January 2017 and June 2021. Minimum of 10 cases required to enter the study

TARPSWG-R2007

Response Evaluation after Neo-adjuvant Chemotherapy for Retroperitoneal Sarcoma

  • PIs: Winan vanHoudt MD (The Netherlands Cancer Institute, Amsterdam, Netherlands); Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
  • Co-I: Sophie Rejjers MD (The Netherlands Cancer Institute, Amsterdam, Netherlands)
  • Status: Closed, Receiving Data from Centers

TARPSWG-R1901

Evaluating a Surgical Complexity Score to predict complications Post-Resection of a Retroperitoneal Sarcoma: A study by the Trans-Atlantic Australasian RPS Working Group (TARPSWG).

  • PI: Mark Fairweather, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US)
  • Co-I: Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US)
  • Status:  Closed, Currently Analyzing Data

TARPSWGR2005

Variations in patterns of care for retroperitoneal sarcoma: a study of the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group

  • PI: Hayden Snow, MD (Peter MacCallum Cancer Center, Melbourne, Australia
  • Co-I: David Gyorki, MD (Peter MacCallum Cancer Center, Melbourne, Australia
  • Status: Closed, Receiving Data from Centers

TARPSWGR2006

Anticipated organs resection and pathologic infiltration – RESAntiPath

  • PIs: Marco Fiore, MD; Alessandro Gronchi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
  • Co-I: Dirk Strauss, MD (Royal Marsden Hospital, London, UK)
  • Status: Closed, Receiving Data from Centers

TARPSWG-R1905 (RESAR Project)

Accuracy and Concordance of Biopsy Diagnosis in Retroperitoneal Sarcoma (BISARC): An International Multi-Institutional Prospective Study by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)

  • PIs: Sinziana Dumitra, MD (MgGill University Health Center, Montreal, Canada) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
  • Co-I: Max Almond, MD (University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK)
  • Status: Closed, Receiving Data from Centers

Published papers

TARPSWG – 1904

An Analysis on Differentiation Changes and Outcomes at the Time of First Recurrence of Retroperitoneal Liposarcoma by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)

  • PIs: Carolyn Nessim, MD, MSc (The Ottawa Hospital, Ottawa, Canada); Sanjay P Bagaria, MD, (Mayo Clinic, Jacksonville, US)
  • Co-Is: Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

TARPSWG – CONSENSUS

Development of an Updated International Consensus on the Management of Primary Retroperitoneal Sarcoma (RPS) by TARPSWG

TARPSWG-1804

Primary Mesenteric Sarcomas – A Collaborative experience by the Trans-Atlantic Australasian RPS Working Group (TARPSWG).

  • PIs: Sam Ford, MD, PhD ; Hannah Tattersall, MD (University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK)
  • Co-I: Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

TARPSWG-1802

Postoperative pancreatic fistula following distal pancreatectomy for primary retroperitoneal sarcoma: an analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)

  • PIs: Sanjay Bagaria, MD (Mayo Clinic, Jacksonville, US) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

TARPSWG-1801

Defining the Role of Neo-Adjuvant Systemic Therapy in High Risk Retroperitoneal Sarcoma: A Multi-Institutional TARPSWG Study

  • PIs: William Tseng MD (University of Southern California, Keck School of Medicine, LA, US ) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

TARPSWG-1902

Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Trans-Atlantic Australasian RPS Working Group (TARPSWG).

  • PIs: Carolyn Nessim, MD, MSc (The Ottawa Hospital, Ottawa, Canada); Guy Lahat, MD, (Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel)
  • Co-Is: Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

TARPSWG-2007

Virtual Biobanking for Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Initiative

PIs: Rebecca Gladdy Md, PhD (University of Toronto); Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

Publication: https://link.springer.com/article/10.1245%2Fs10434-020-08775-1

TARPSWG-1903

Patterns of Recurrence and Survival Probability following Second Relapse of Retroperitoneal Sarcoma: A Study from TARPSWG

  • PIs: Winan vanHoudt, MD (The Netherlands Cancer Institute, Amsterdam Netherlands) ; Rebecca Gladdy, MD, PhD (Mount Sinai Hospital, Princess Margaret Hospital, University of Toronto, Toronto, Canada)
  • Co-I: Marco Fiore, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Italy)

TARPSWG-1700

Intercontinental Collaborative Experience with abdominal, retroperitoneal and pelvic schwannomas.

  • PIs: Sam Ford MD, PhD (University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

TARPSWG-1701

Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG

  • PIs: Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

TARPSWG-1702

Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma.

  • PIs: William Tseng MD (University of Southern California, Keck School of Medicine, LA, US ) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

TARPSWG-1806

Identifying the Minimum Volume Threshold for Retroperitoneal Soft Tissue Sarcoma Resection: Merging National Data with Consensus Expert Opinion.

  • PIs: Waddah Al-Rafaie, MD (MedStar Georgetown University Hospital, Washington, DC)
  • Co-Is: Anthony M. Villano, MD, Alexander Zeymo, MS, Suzanne O’Neill, PhD, (MedStar Georgetown University Hospital, Washington, DC)

TARPSWG

Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS) A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group

  • PIs: Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
  • Co-Is: Carol Swallow (University of Toronto); Dirk Strauss (Royal Marsden); Sylvie Bonavalot (Institut Curie) et al.

TARPSWG

Post-relapse Outcomes After Primary Extended Resection of Retroperitoneal Sarcoma: A Report From the Trans-Atlantic RPS Working Group

  • PIs: Carol Swallow (University of Toronto); Andrea MacNeill (Vancouver)
  • Co-Is: Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy); Dirk Strauss (Royal Marsden); Sylvie Bonavalot (Institut Curie) et al.

TARPSWG

Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma A Report From the Transatlantic RPS Working Group

  • PIs: Dirk Strauss (Royal Marsden); Andrea MacNeill (Vancouver)
  • Co-Is: Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US) ; Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy); Sylvie Bonavalot (Institut Curie); Carol Swallow (Unvisersity of Toronto) et al.
  • Publication:https://tarpswg.files.wordpress.com/2017/05/morbidity-tarpswg.pdf

TARPSWG

Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group

  • PIs: Rick Hass (The Netherlands Cancer Institute); Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
  • Co-Is: Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US) ; Sylvie Bonavalot (Institut Curie); Carol Swallow (Unvisersity of Toronto); Piotr Rutkowski (Maria Sklodowska‐Curie Institute–Oncology Center) et al.

TARPSWG

External validation of a multi-institutional retroperitoneal sarcoma nomogram

  • PIs: Chandrajit Raut, MD (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, US); Alessandro Gronchi, MD (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
  • Co-Is: Sylvie Bonavalot (Institut Curie); Carol Swallow (Unvisersity of Toronto); Piotr Rutkowski (Maria Sklodowska‐Curie Institute–Oncology Center); Peter Hohenberger (Mannheim University); Dirk Strauss (Royal Marsden) et al.

TARPSWG – CONSENSUS

Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group

TARPSWG – CONSENSUS

Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group

TARPSWG – CONSENSUS

Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)

%d bloggers like this: